---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-22-006803"
form_type: "8-K"
ticker: "PMCB"
cik: "0001157075"
company_name: "PharmaCyte Biotech, Inc."
filed_at: "2022-10-07T23:59:59+00:00"
generated_at: "2026-06-23T04:38:15.031543+00:00"
event_type: "leadership"
sentiment: "negative"
materiality_score: 0.8
calibrated_materiality_score: 0.8
confidence: "high"
source: SEC EDGAR
---

# PharmaCyte CEO resigns; interim CEO appointed; Board forms Business Review Committee to evaluate strategic options

## Summary
- CEO Kenneth Waggoner resigned effective Oct 6; separation agreement provides $216,667 lump sum and $433,333 consulting payments over 12 months.
- Board appointed Joshua Silverman as interim CEO and Chairman; Silverman is a director since Aug 2022 and co-founder of Parkfield Funding.
- Board's Business Review Committee to evaluate opportunities including FDA clinical hold on Cell-in-a-Box IND and relationship with SG Austria.
- Company continuing share repurchase program of up to $10 million; spending on programs curtailed pending review.

## SEC filing metadata
- accession: 0001683168-22-006803
- form_type: 8-K
- ticker: PMCB
- cik: 0001157075
- company_name: PharmaCyte Biotech, Inc.
- filed_at: 2022-10-07T23:59:59+00:00
- event_type: leadership
- sentiment: negative
- materiality_score: 0.8
- calibrated_materiality_score: 0.8
- confidence: high
- sec_items: 5.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/0001683168-22-006803-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/pharmacyte_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-22-006803
- JSON: https://secwatch.observer/filing/0001683168-22-006803.json
- Plain text: https://secwatch.observer/filing/0001683168-22-006803.txt

## Key facts
- Executive change
  Joshua N. Silverman was appointed as interim Chairman of the Board, interim Chief Executive Officer and interim President at PharmaCyte Biotech, Inc..
  - Action: appointed
  - Role: interim Chairman of the Board, interim Chief Executive Officer and interim President
  source text: Effective October 6, 2022, the Board appointed Joshua N. Silverman, a director on the Board since August 2022, as interim Chairman of the Board, interim Chief Executive Officer and interim President of the Company.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/0001683168-22-006803-index.htm
- Executive change
  Kenneth L. Waggoner resigned as Chief Executive Officer, President and General Counsel at PharmaCyte Biotech, Inc..
  - Action: resigned
  - Role: Chief Executive Officer, President and General Counsel
  source text: Kenneth L. Waggoner, the Chief Executive Officer, President and General Counsel of PharmaCyte Biotech , Inc. ( the “Company”) resigned from his position as an employee of the Company and its direct and indirect subsidiaries and affiliates (collectively, the “Company Group”) and as a director on the Board of Directors of the Company (the “Board”).
  evidence_url: https://www.sec.gov/Archives/edgar/data/1157075/000168316822006803/0001683168-22-006803-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.